Research programme: Alzheimer's disease therapeutics - Pharnext/Biosystems
Latest Information Update: 25 Jun 2014
At a glance
- Originator BioSystems International; INSERM; Pharnext; University of Bordeaux
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Alzheimer's disease
Most Recent Events
- 25 Jun 2014 Preclinical trials in Alzheimer's disease in France (unspecified route)